Table 1.
Patient’s characteristics (N = 46).
| Age (m, ±SD) | 61.8 ± 6.6 years | |
|---|---|---|
| Sex (n, %) | Women 11 (23.9) | |
| Men 35 (76.1) | ||
| Histological type (n, %) | NSCLC-NOS 5 (10.9) | |
| Neuroendocrine 1 (2.1) | ||
| Squamous cell carcinoma 15 (32.7) | ||
| Adenocarcinoma 25 (54.3) | ||
| Tumor location (n, %) | Right upper lobe 20 (43.5) | |
| Middle lobe 2 (4.3) | ||
| Right lower lobe 12 (26.1) | ||
| Left upper lobe 8 (17.4) | ||
| Left lower lobe 4 (8.7) | ||
| N2 disease location | Subcarinal 16 (34.7) | |
| Right lower paratracheal 22 (47.9) | ||
| Left lower paratracheal 8 (17.4) | ||
| Previous diagnostic method | Mediastinoscopy 3 (6.5) | |
| EBUS-TBNA 43 (93.5) | ||
| Induction therapy (n, %) | Chemoradiotherapy 42 (91.3) | Cisplatin etoposide 1 |
| Cisplatin vinorelbine 30 | ||
| Carboplatin vinorelbine 11 | ||
| Chemoradiotherapy + immunotherapy 3 (6.5) | ||
| Chemotherapy + immunotherapy 1 (2.2) | ||
| Radiotherapy dose (m, ±SD) | 58.3 Gy ±3.9 | |
| Time between end of induction therapy and EBUS-TBNA (m, ±SD) | 5.1 weeks ±1.7 | |
| Time between EBUS-TBNA and resection (m, ±SD) | 34.6 days ±11.2 | |
| Number of mediastinal stations sampled during EBUS-TBNA (m, ±SD) | 1.22 ± 0.44 | |
| Number of passes during EBUS-TBNA (m, ±SD) | 5.1 ± 2.4 | |
| Number of lymph nodes dissected during VAMLA (m, ±SD) | 11.2 ± 6.2 | |
| Number of mediastinal stations dissected during VAMLA (m, ±SD) | 3 ± 0.63 | |
| Resection surgery (n, %) (N = 26) | Sublobar resection 2 (7.7) | |
| Lobectomy 20 (76.9) | ||
| Bilobectomy 4 (15.4) | ||
| Final N status (n, %) | Persistent N2 disease 19 (41.3) | |
| Downstaging 27 (58.7) | ||
| Time between EBUS-TBNA and VAMLA (m, ±SD) | 20.3 days ±8.3 | |
| Time between EBUS-TBNA and resection (m, ±SD) | 34.6 days ±11.2 | |
| Time between VAMLA and resection (m, ±SD) | 14.3 days ±8.3 | |
| Operative time during resection after induction (m, ±SD) | 203 min ±49.8 | |
EBUS-TBNA, endobronchial ultrasound-guided transbronchial needle aspiration; m, mean; n, number; NSCLC-NOS, non-small cell lung cancer-not otherwise specified; SD, standard deviation; VAMLA, video-assisted mediastinoscopic lymphadenectomy.